Higher rebates for brand-name drugs result in lower costs for Medicaid compared to Medicare Part D.
- Physical Description: 1 online resource (iv, 22 pages) : color illustrations
- Publisher: [Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, 2011.
|General Note:|| Title from title screen (viewed June 23, 2016).
|Bibliography, etc. Note:|| Includes bibliographical references.
Search for related items by subject
Pharmaceutical services insurance > United States > Auditing.
Drugs > Prices > United States.
Brand name products > Prices > United States.